Evidence map›Paper›PMID 31675380›Full record

Observational studyPloS one2019

Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR).

Michela Buglione, Marianna Noale, Alessio Bruni, Alessandro Antonelli, Filippo Bertoni, Renzo Corvo', Umberto Ricardi, Paolo Borghetti, Marta Maddalo, Claudio Simeone and 14 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Postoperative radiotherapy after upfront radical prostatectomy: debated issues at a turning point-a survey exploring management trends on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 13 institutions in 3 countries.

Michela BuglioneRadiation Oncology Department, University and Spedali Civili Hospital, Brescia, Italy.
Marianna NoaleNational Research Council, Neuroscience Institute, Aging Branch, Padua, Italy.ORCID 0000-0001-7115-139X
Alessio BruniRadiotherapy Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.ORCID 0000-0003-1068-5958
Alessandro AntonelliDepartment of Urology, University and Spedali Civili Hospital, Brescia, Italy.
Filippo BertoniRadiotherapy Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Renzo Corvo'Department of Radiation Oncology, University Hospital "Policlinico San Martino", Genoa, Italy.
Umberto RicardiRadiation Oncology Unit, Department of Oncology, School of Medicine-University of Turin, Turin, Italy.
Paolo BorghettiRadiation Oncology Department, University and Spedali Civili Hospital, Brescia, Italy.
Marta MaddaloRadiation Oncology Department, University and Spedali Civili Hospital, Brescia, Italy.
Claudio SimeoneDepartment of Urology, University and Spedali Civili Hospital, Brescia, Italy.
Ercole MazzeoRadiotherapy Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Angelo PorrecaDepartment of Robotic Urological Surgery, Abano Terme Hospital, Abano Terme, Padua, Italy.
Sergio SerniDepartment of Urologic Robotic Surgery and Renal Transplantation, Careggi University Hospital, Florence, Italy.
Pierfrancesco BassiDepartment of Urology, Catholic University of Rome, Policlinico Gemelli, Rome, Italy.
Mauro GacciDepartment of Urologic Robotic Surgery and Renal Transplantation, Careggi University Hospital, Florence, Italy.
Vincenzo MironeUrology Unit, University Federico II, Naples, Italy.
Rodolfo MontironiSection of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine-Ospedali Riuniti, Ancona, Italy.
Andrea TubaroUrology Unit, Sant'Andrea Hospital, "La Sapienza" University, Rome, Italy.
Alfredo BerrutiMedical Oncology Unit, ASST-Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Giario Natale ContiUrology Unit, ASST Lariana, Sant'Anna Hospital, Como, Italy.
Stefania MaggiNational Research Council, Neuroscience Institute, Aging Branch, Padua, Italy.
Stefano Maria MagriniRadiation Oncology Department, University and Spedali Civili Hospital, Brescia, Italy.
Luca TriggianiRadiation Oncology Department, University and Spedali Civili Hospital, Brescia, Italy.
Pros-IT CNR study group
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITUniversity of Modena and Reggio Emilia · ITAzienda Ospedaliero-Universitaria Careggi · ITNeuroscience Institute · ITAgostino Gemelli University Polyclinic · ITAzienda Socio Sanitaria Territoriale Lariana · ITCTO Andrea Alesini · ITDepartment of Medical Sciences · BYFederico II University Hospital · ITMarche Polytechnic University · ITMartin University · USPoliclinico Abano Terme · ITUniversity of Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are several treatments available to newly diagnosed prostate cancer (PCA) patients. Although surgery and radiotherapy (RT) with or without androgen deprivation therapy (ADT) are widely adopted treatment options for localized PCA together with active surveillance (AS), there is no consensus nor randomised trials on treatment selection, prospective quality of life (QOL), along with toxicity outcomes and according to treatment modality in the Italian population. The current study aimed to describe clinical-therapeutic features and QOL at PCA diagnosis, according to different treatment patterns in a large prospective, Italian population, enrolled in the Pros-IT CNR study.

methodsThe Pros-IT CNR is an on-going national, multicenter, observational, prospective study on patients affected by PCA who have been referred by 97 Italian Urology, Radiation Oncology and Medical Oncology facilities participating in the project. The possible relationships between the treatment patterns reported in the 6 month follow-up case report form and patients' features at diagnosis were evaluated using exploratory multiple correspondence analysis (MCA) and other data analysis method.

resultsAt diagnosis, surgery and AS patients were significantly younger, had fewer comorbidities, lower PSA levels and Gleason Score (GS) values; they were also diagnosed at an earlier stage of disease with respect to the RT or ADT patients who showed significantly worse QoL scores at the time of diagnosis.

conclusionsAn analysis of the data collected at baseline and 6 months later uncovered substantial differences in ages, comorbidities, clinical and QOL features in the various treatment groups. These findings do not fully reflect the current PCA treatment guidelines and suggest the need for a multidisciplinary consensus guideline to ameliorate both the counselling and treatments of PCA patients.

Indexed as

Critical PathwaysAgedAged, 80 and overHumansItalyMaleMiddle AgedNeoplasm GradingProspective StudiesProstatic NeoplasmsQuality of LifeTreatment Outcome

Identifiers

PMID31675380
PMCPMC6824566
OpenAlexW2987685822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.